Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Good Corporate Governance
Today Cambridge Cognition Holdings Plc issued an RNS which at first glance seems ok, but is it?
The purpose of a Nomad is to guide the Company and ensure they adhere to the rules & regulations.
So, there are some additional Director disclosures which I have no concern about except that your previous Nomad (finnCap Ltd) appears not to have fully disclosed.
On Companies House if you click on the Directors, you will be able to access all their previous Appointments.
The question that I would be asking is, why do they need a replacement Nomad and Joint Broker?
I have had previous experience of a Company changing their Nomad and appointing a joint Broker and then there was a placing later that day and a Broker resigned.
For the avoidance of doubt, I am not implying there is anything untoward with your Company, only that a Nomad has a duty of care to the Company and should have disclosed the information on the Appendix at the bottom of today’s RNS years ago and it should not have taken a new Nomad to inform the Market of the information.
Full credit to your new Nomad for doing proper due diligence.
RKB
That’s a coincidence that we got an rns. Just not really the calibre of the usual ones. Surprised at the drop don’t really see what the issue is. Someone has been involved in a company that liquidated is hardly big news.
Brought a few more at 122 we are due an rns.
Good start to the year long may it continue
Cambridge Cognition wins £2.1 million contract to provide digital assessments for two neurodegenerative disease clinical trials
Cambridge Cognition Holdings Plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to announce that it has been awarded contracts worth £2.1 million to provide cognitive assessments, electronic diaries, and third-party hardware for two clinical trials in neurodegenerative disease. Revenue is expected over the next three financial years.
Neurodegenerative disease represents a major global medical need. If treatments are not developed soon, then it is estimated that more than 12 million Americans will be living with neurodegenerative diseases by 20501. Cognitive dysfunction is a hallmark of many neurodegenerative diseases and so sensitive and specific cognitive assessment are essential in developing effective treatments. With unrivalled use in over 2,500 peer-reviewed publications, Cambridge Cognition's digital cognitive assessments offer customers outstanding sensitivity and specificity.
A US biotechnology company that has worked with Cambridge Cognition previously is investigating the effect of a new drug in two neurodegenerative diseases. With some data being collected in clinic and further insights taken at home, these two clinical trials are being run in a hybrid or part-virtual manner.
Cambridge Cognition has been contracted to deliver both elements: providing gold-standard, computerized cognitive assessments (CANTABTM) for use in clinics, as well as daily tests of cognition and a patient diary to track other symptoms via a mobile app. This blend of in-clinic and at home monitoring can provide much more detailed insights into the development of disease over time and the efficacy of new pharmaceutical compounds. The electronic diaries for the trials are being provided using the Company's electronic Clinical Outcomes Assessment (eCOA) platform. The Company is also providing third party hardware for use in clinics and at home.
Love COG. Attracted to them, as being a taxi driver I was astounded by what great business clinical trials are to my work. Huge fares to get people to hospitals/clinics from far flung locations, that COG can now mitigate against.
Fortunately I put my money where my mouth is on this occasion ;)
Good prediction elguiri
I’d suggest that this reads more than ‘nicely’!
This really should spark a significant rerate. The fundamentals here are fantastic :)
Growth in revenues of 50% to £10.1 million (2020: £6.7 million)
· Increase in contracted order backlog of 51% to £17.0 million (31 December 2020: £11.2 million)
· Profit after tax for the year of £0.5 million (2020: £0.4 million loss)
· Cash balance of £6.8 million at 31 December 2021 (31 December 2020: £3.0 million
This reads nicely
Growth in revenues of 50% to £10.1 million (2020: £6.7 million)
· Increase in contracted order backlog of 51% to £17.0 million (31 December 2020: £11.2 million)
· Profit after tax for the year of £0.5 million (2020: £0.4 million loss)
· Cash balance of £6.8 million at 31 December 2021 (31 December 2020: £3.0 million)
Nice steady growth hopefully start moving back towards highs with some more good news flow like the above
Thanks for your inputs. I could find no info on any problems, so was just wondering why the fall. Markets are super jittery at present.
Plenty of panic selling over Russia and Ukraine can be thrown in the mix aswell. Putin could probably do with a cantab examination lol
In the meantime nothing’s changed at COG!
Yep - got to undermine the whole tech and green sector by snuffing out inflation.
Can anyone advise on the recent falls, are we just following the Tech drop or is there more?
Would be nice to get back over 130 today fingers crossed. Glad we are working with top 20 pharma definitely helps in building a good reputation.
Well done COG - doing good things.
Cambridge Cognition announces new major pharma client for schizophrenia clinical trials
Love the direction things are now going with Cambridge Cog. Real inertia in the business now. Certainly a great place to squirrel some money away from the vagrancies of the pandemic.
Anyone noticed lse says there’s 2 RNS I can only see 1? Good news on the contract btw keep the order book looking healthy
Electronic Clinical Outcomes Assessment contract win worth over £500,000
Not been on here for a while, but I bought in on the drop to the late 130s. Thought I'd got the bottom but it's drifted further. However, interesting about the grant of options announced last month, with triggers being 170p and 220p. That's reassurance if ever you need. Might top up further if it stays down this level
Keeps us ticking over til the new year lol
Cambridge Cognition wins £1.0m schizophrenia clinical trial contract